An independent Centers for Disease Control and Prevention advisory committee today recommended immediate resumption of the administration of Johnson & Johnson’s COVID-19 vaccine in the U.S. The vaccine maker would add a warning to its labeling materials about the risk of rare blood clots known as thrombosis with thrombocytopenia syndrome. The recommendation, which passed by a 10-4 vote with one abstention, now goes to the CDC for its approval. The Food and Drug Administration will amend Johnson & Johnson’s emergency use authorization to indicate that women under the age of 50 should be aware of the risk of blood clots from the vaccine.

CDC’s Clinician Outreach and Communication Activity will hold a Zoom call Tuesday, April 27 at 2 p.m. ET to discuss the latest evidence on thrombosis with thrombocytopenia syndrome after the administration of the Johnson & Johnson vaccine. Access the live webinar here, a recording of which will be available several hours after the live event ends.
 

Related News Articles

Headline
The Centers for Disease Control and Prevention's COVID-19 data tracker shows an 18.1% test positivity rate for the week ending Aug. 10, the highest it has been…
Headline
The Centers for Disease Control and Prevention Aug. 13 issued an advisory alerting of an uptick of cases of parvovirus B19 across the U.S. Parvovirus B19 is a…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…